Cancer vaccine in combination with radiopharmaceutical therapy (RPT) upregulates type I interferon pathway in Ovalbumin-expressing tumor model 2254330
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.218 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Daeun Shim und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
To enhance the efficacy of therapeutic cancer vaccines, combination strategies are needed to overcome mechanisms of immunoresistance. RPT, such as pan-cancer targeting 90Y-NM600, can act as an immunomodulating agent. We have previously found that cancer vaccines administered prior to RPT elicited greater anti-tumor response in murine models than if administered after RPT. Here, we investigated the mechanisms by which combination treatment of vaccine prior to RPT enhanced antitumor immunity using an ovalbumin-expressing tumor model.
Methods
1x106 E.G7-OVA-PD-L1hi tumor cells were subcutaneously implanted in C57Bl/6 mice. 0.5x106 naïve OT-I CD8+ T cells were transferred to the tumor-bearing mice (day -3), followed by vaccination with OVA-encoding DNA plasmid (day -2), and low dose 90Y-NM600 injection (delivering 5Gy to the tumor; day 0). Tumors were collected 7- and 14-days post-RPT for transcriptomic analysis and flow cytometry. In a follow up study, mice were similarly treated, and concurrently treated or not with a STING antagonist H-151, and followed for changes in tumor growth.
Results
Combining tumor vaccine with RPT significantly upregulated genes associated with type I interferon pathway along with increased cytotoxic and CD8+ T cell scores. This finding aligned with increased infiltration of SIINFEKL-specific CD8+ T cells 7 days post-RPT. Genes associated with cytotoxicity significantly decreased 14 days post-RPT. Addition of H-151 did not affect tumor growth.
Conclusion
RPT enhanced the infiltration and functional activity of vaccine-activated tumor-specific CD8+ T cells, likely through STING-independent type I interferon signaling. Funding Source T32 CA009135 F31CA305954 P01 CA250972 Topic Categories Vaccines and Immunotherapy (VAC)
Zitieren
APA
Shim, D., Mouton, C., Moseman, J., Rojas, H. C., Idrissou, M. B., Hernandez, R., & McNeel, D. (2026). Cancer vaccine in combination with radiopharmaceutical therapy (RPT) upregulates type I interferon pathway in Ovalbumin-expressing tumor model 2254330. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.218
Vancouver
Shim D, Mouton C, Moseman J, Rojas HC, Idrissou MB, Hernandez R, et al. Cancer vaccine in combination with radiopharmaceutical therapy (RPT) upregulates type I interferon pathway in Ovalbumin-expressing tumor model 2254330. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.218
BibTeX
@article{Shim2026,
author = {Shim, Daeun and Mouton, Colette and Moseman, Jena and Rojas, Hansel Comas and Idrissou, Malick Bio and Hernandez, Reinier and McNeel, Douglas},
title = {Cancer vaccine in combination with radiopharmaceutical therapy (RPT) upregulates type I interferon pathway in Ovalbumin-expressing tumor model 2254330},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.218}
}
EUVIMED